These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 25261632)

  • 21. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Somatic alterations as the basis for resistance to targeted therapies.
    Blair BG; Bardelli A; Park BH
    J Pathol; 2014 Jan; 232(2):244-54. PubMed ID: 24114654
    [TBL] [Abstract][Full Text] [Related]  

  • 23. c-MET kinase inhibitors: a patent review (2011 - 2013).
    Zhu K; Kong X; Zhao D; Liang Z; Luo C
    Expert Opin Ther Pat; 2014 Feb; 24(2):217-30. PubMed ID: 24266843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protein kinases as targets for cancer treatment.
    Giamas G; Stebbing J; Vorgias CE; Knippschild U
    Pharmacogenomics; 2007 Aug; 8(8):1005-16. PubMed ID: 17716234
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical and clinical development of novel agents that target the protein kinase C family.
    Serova M; Ghoul A; Benhadji KA; Cvitkovic E; Faivre S; Calvo F; Lokiec F; Raymond E
    Semin Oncol; 2006 Aug; 33(4):466-78. PubMed ID: 16890801
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is there a future for Aurora kinase inhibitors for anticancer therapy?
    Carpinelli P; Moll J
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):533-42. PubMed ID: 19562649
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kinases as targets in the treatment of solid tumors.
    Giamas G; Man YL; Hirner H; Bischof J; Kramer K; Khan K; Ahmed SS; Stebbing J; Knippschild U
    Cell Signal; 2010 Jul; 22(7):984-1002. PubMed ID: 20096351
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted cancer therapy: promise and reality.
    Klein S; Levitzki A
    Adv Cancer Res; 2007; 97():295-319. PubMed ID: 17419951
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Array-based pharmacogenomics of molecular-targeted therapies in oncology.
    Sanoudou D; Mountzios G; Arvanitis DA; Pectasides D
    Pharmacogenomics J; 2012 Jun; 12(3):185-96. PubMed ID: 22249357
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimising translational oncology in clinical practice: strategies to accelerate progress in drug development.
    Stahel R; Bogaerts J; Ciardiello F; de Ruysscher D; Dubsky P; Ducreux M; Finn S; Laurent-Puig P; Peters S; Piccart M; Smit E; Sotiriou C; Tejpar S; Van Cutsem E; Tabernero J
    Cancer Treat Rev; 2015 Feb; 41(2):129-35. PubMed ID: 25533737
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Signal transduction therapy of cancer.
    Levitzki A; Klein S
    Mol Aspects Med; 2010 Aug; 31(4):287-329. PubMed ID: 20451549
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Beyond chemotherapy--demystifying the new 'targeted' cancer treatments.
    Dear R; Wilcken N; Shannon J
    Aust Fam Physician; 2008; 37(1-2):45-9. PubMed ID: 18239753
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanisms of drug inhibition of signalling molecules.
    Sebolt-Leopold JS; English JM
    Nature; 2006 May; 441(7092):457-62. PubMed ID: 16724058
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fibroblast growth factor receptor 2: a therapeutic target in gastric cancer.
    Hong L; Han Y; Liu J; Brain L
    Expert Rev Gastroenterol Hepatol; 2013 Nov; 7(8):759-65. PubMed ID: 24134151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update.
    Arunesh GM; Shanthi E; Krishna MH; Sooriya Kumar J; Viswanadhan VN
    Expert Opin Ther Pat; 2014 Jan; 24(1):5-17. PubMed ID: 24131033
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Protein tyrosine kinase inhibitors in cancer therapy].
    Boutayeb S; Zakkouri FZ; Aitelhaj M; Mesmoudi M; Boutayeb A; Boutayeb W; Mrabti H; Errihani H
    Pathol Biol (Paris); 2012 Aug; 60(4):229-33. PubMed ID: 22743095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sphingosine kinase/sphingosine 1-phosphate signaling in cancer therapeutics and drug resistance.
    Selvam SP; Ogretmen B
    Handb Exp Pharmacol; 2013; (216):3-27. PubMed ID: 23563649
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The development of molecularly targeted anticancer therapies: an Eli Lilly and Company perspective.
    Perry WL; Weitzman A
    Clin Adv Hematol Oncol; 2005 Mar; 3(3):199-202, 237-8. PubMed ID: 16166991
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment.
    Vella LJ; Andrews MC; Behren A; Cebon J; Woods K
    Expert Rev Clin Immunol; 2014 Aug; 10(8):1107-23. PubMed ID: 24939732
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The signal transduction pathway of multi-target kinase inhibitors as anticancer agents in clinical use or in phase III].
    Wu W; Lu C; Chen SY; Yu NF
    Yao Xue Xue Bao; 2009 Mar; 44(3):242-57. PubMed ID: 19449520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.